GlobeNewsWire
07 Jan 2026, 21:27 UTC · 36w ago
Verdict
Headline takes no side. We score GMED +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Globus Medical established full year 2026 revenue guidance between $3.18 billion and $3.22 billion with non-GAAP EPS between $4.30 and $4.40.
So whatForward-looking guidance is the primary driver of stock valuation and provides a concrete benchmark for 2026 growth expectations.
More positive than 92% of claims this week
Preliminary fourth quarter 2025 sales are expected to reach approximately $823.2 million, a 25.2% increase over the prior year.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 85% of claims this week
Full year 2025 sales are expected to be approximately $2.936 billion, marking a 16.5% increase over the previous year.
More positive than 76% of claims this week
Excluding Nevro sales, the Globus base business revenue for Q4 was $723.3 million, reflecting 10.0% organic growth.
More positive than 61% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Company reported preliminary record sales results for Q4 and full year 2025 with strong revenue growth and positive 2026 guidance.
More positive than 96% of relationship scores this week
[a_to_b] Globus Medical integrated the Nevro acquisition.
More positive than 96% of relationship scores this week
[b_to_a] Nevro is identified as a recently acquired subsidiary of Globus Medical.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−17.1%
Price is moving against the score
$75.08 vs $90.54 close before publication (Jan 7) · not market-adjusted
GMED chart →